<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: financial goals", fill: "#836953"},
{source: "1: financial goals", target: "1: operations", fill: "#836953"},
{source: "1: operations", target: "1: technical risks associated with", fill: "#836953"},
{source: "1: technical risks associated with", target: "1: new products", fill: "#836953"},
{source: "1: financial goals", target: "5: continuing decline", fill: "#96c"},
{source: "5: continuing decline", target: "5: significant", fill: "#96c"},
{source: "5: significant", target: "5: adverse impact on", fill: "#96c"},
{source: "5: continuing decline", target: "8: development", fill: "#edc9af"},
{source: "8: development", target: "8: expenditures which may increase", fill: "#edc9af"},
{source: "8: development", target: "9: significant", fill: "#bf94e4"},
{source: "9: significant", target: "9: shareholders equity could adversely impact", fill: "#bf94e4"},
{source: "9: shareholders equity could adversely impact", target: "9: in the NASDAQ Capital Market ", fill: "#bf94e4"},
{source: "9: significant", target: "14: license products technologies", fill: "#0bda51"},
{source: "14: license products technologies", target: "14: corporate costs primarily", fill: "#0bda51"},
{source: "14: corporate costs primarily", target: "14: preferred stock dividends", fill: "#0bda51"},
{source: "14: license products technologies", target: "25: listing on", fill: "#c71585"},
{source: "25: listing on", target: "25: NASDAQ Capital Market ", fill: "#c71585"},
{source: "25: NASDAQ Capital Market ", target: "25: stockholders", fill: "#c71585"},
{source: "25: stockholders", target: "25: ii market value", fill: "#c71585"},
{source: "25: ii market value", target: "25: common stock", fill: "#c71585"},
{source: "25: listing on", target: "45: technical performance", fill: "#3fff00"},
{source: "45: technical performance", target: "45: BioSentry ", fill: "#3fff00"},
{source: "45: BioSentry ", target: "45: product lines", fill: "#3fff00"},
{source: "45: product lines", target: "45: dependent", fill: "#3fff00"},
{source: "45: dependent", target: "45: Companys ", fill: "#3fff00"},
{source: "45: Companys ", target: "45: potential market", fill: "#3fff00"},
{source: "45: potential market", target: "45: such systems", fill: "#3fff00"},
{source: "45: technical performance", target: "START_HERE", fill: "#3fff00"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Semiconductors and Semiconductor Equipment</td>
    </tr>
    <tr>
      <td>Semiconductor Equipment</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Bombings</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_director">Operations director</a></td>
      <td>The role of operations director generally encompasses the oversight of operational aspects of company strategy with responsibilities to ensure operation information is supplied to the chief executive and the board of directors as well as external parties.\n\n\n== Description ==\nThe role of operations director can vary according to the size of a company, and at some companies many even encompass some or all the functions of a chief operating officer.The Institute of Directors of the United Kingdom defines the role as overseeing "all operational aspects of company strategy" and "responsible for the flow of operations information to the chief executive, the board and, where necessary, external parties such as investors or financial institutions".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Timeline_of_Apple_Inc._products">Timeline of Apple Inc. products</a></td>
      <td>This timeline of Apple Inc. products is a list of all stand-alone Apple II, Macintosh, and other computers, as well as computer peripherals, expansion cards, ancillary products, and consumer electronics sold by Apple Inc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_design">Product design</a></td>
      <td>Product design as a verb is to create a new product to be sold by a business to its customers. A very broad coefficient and effective generation and development of ideas through a process that leads to new products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gross_domestic_product">Gross domestic product</a></td>
      <td>Gross domestic product (GDP) is a monetary measure of the market value of all the final goods and services produced in a specific time period by countries. GDP (nominal) per capita does not, however, reflect differences in the cost of living and the inflation rates of the countries; therefore, using a basis of GDP per capita at purchasing power parity (PPP) may be more useful when comparing living standards between nations, while nominal GDP is more useful comparing national economies on the international market.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Godrej_Consumer_Products">Godrej Consumer Products</a></td>
      <td>Godrej Consumer Products Limited (GCPL) is an Indian consumer goods company based in Mumbai, India. GCPL's products include soap, hair colourants, toiletries and liquid detergents.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_strategy">Product strategy</a></td>
      <td>Product strategy defines the high-level plan for developing and marketing a product, how the product supports the business strategy and goals, and is brought to life through product roadmaps. A product strategy describes a vision of the future with this product, the ideal customer profile and market to serve, go-to-market and positioning (marketing), thematic areas of investment, and measures of success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Burger_King_products">Burger King products</a></td>
      <td>When the predecessor of international fast food restaurant chain Burger King (BK) first opened in 1953, its menu predominantly consisted of hamburgers, French fries, soft drinks, milkshakes, and desserts. After being acquired by its Miami, Florida franchisees and renamed in 1954, BK began expanding its menu by adding the Whopper sandwich in 1957, and has since added non-beef items such as chicken, fish, and vegetarian offerings, including salads and meatless sandwiches.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Diversification_(marketing_strategy)">Diversification (marketing strategy)</a></td>
      <td>Diversification is a corporate strategy to enter into a new products or product lines, new services or new markets, involving substantially different skills, technology and knowledge.\nDiversification is one of the four main growth strategies defined by Igor Ansoff in the Ansoff Matrix:\nAnsoff pointed out that a diversification strategy stands apart from the other three strategies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_form">Significant form</a></td>
      <td>Significant form refers to an aesthetic theory developed by English art critic Clive Bell which specified a set of criteria for what qualified as a work of art.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statistical_significance">Statistical significance</a></td>
      <td>In statistical hypothesis testing, a result has statistical significance when it is very unlikely to have occurred given the null hypothesis. More precisely, a study's defined significance level, denoted by \n  \n    \n      \n        α\n      \n    \n    {\displaystyle \alpha }\n  , is the probability of the study rejecting the null hypothesis, given that the null hypothesis is true; and the p-value of a result, \n  \n    \n      \n        p\n      \n    \n    {\displaystyle p}\n  , is the probability of obtaining a result at least as extreme, given that the null hypothesis is true.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Mother">Significant Mother</a></td>
      <td>Significant Mother is an American television sitcom created by Erin Cardillo and Richard Keith. Starring Josh Zuckerman, Nathaniel Buzolic and Krista Allen, it premiered on The CW network on August 3 and ended its run on October 5, 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_development">Business development</a></td>
      <td>Business development entails tasks and processes to develop and implement growth opportunities within and between organizations. It is a subset of the fields of business, commerce and organizational theory.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Forearm_(comics)">Forearm (comics)</a></td>
      <td>Forearm (Michael McCain) is a fictional mutant villain appearing in American comic books published by Marvel Comics. As a member of the Mutant Liberation Front, Forearm has always been a mainstay on the terrorist group's roster, even staying through leader changes and incarceration.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Justin_Thomas">Justin Thomas</a></td>
      <td>Justin Louis Thomas (born April 29, 1993) is an American professional golfer who plays on the PGA Tour and is former World Number One. In 2017, Thomas experienced a breakout year, winning five PGA Tour events and the FedEx Cup championship.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ultron">Ultron</a></td>
      <td>Ultron () is a supervillain appearing in American comic books published by Marvel Comics. The character was created by writer Roy Thomas and artist John Buscema, and initially made his debut as an unnamed character in The Avengers #54 (July 1968), with his first full appearance in The Avengers #55 (August 1968).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Jordan_Spieth">Jordan Spieth</a></td>
      <td>Jordan Alexander Spieth (born July 27, 1993) is an American professional golfer on the PGA Tour and former world number one in the Official World Golf Ranking. He is a three-time major winner and the 2015 FedEx Cup champion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Maryland">Maryland</a></td>
      <td>Maryland (US:  (listen) MERR-il-ənd) is a state in the Mid-Atlantic region of the United States. It shares borders with Virginia, West Virginia, and the District of Columbia to its south and west; Pennsylvania to its north; and Delaware and the Atlantic Ocean to its east.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Patton_Oswalt">Patton Oswalt</a></td>
      <td>Patton Oswalt (born January 27, 1969) is an American stand-up comedian, actor, and screenwriter. He starred as Spence Olchin in the sitcom The King of Queens (1998–2007) and narrated the sitcom The Goldbergs (2013–present) as adult Adam F. Goldberg.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>JMAR TECHNOLOGIES INC      Item 1A RISK FACTORS          Our ability to achieve our operating and <font color="blue">financial goals</font> is subject to     a number of risks, including risks relating to our business <font color="blue">operations</font>, our     ability to finance our <font color="blue">operations</font>, and <font color="blue">technical <font color="blue">risks associated with</font></font> our     <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">risks actually</font> occur, our business, operating     results, prospects or <font color="blue">financial condition could</font> be <font color="blue">materially</font> and <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td><font color="blue">Additional     </font>risks not <font color="blue">presently known</font> to us or that we currently deem <font color="blue">immaterial may</font>     also affect our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">continuing decline</font> in revenues and our net and operating losses are     <font color="blue">significant</font> and could have an <font color="blue">adverse impact on</font> our stock price</td>
    </tr>
    <tr>
      <td>Our revenues for the years ended <font color="blue">December </font>31, 2005, 2004 and 2003 were     dlra9cmam163cmam520, dlra10cmam059cmam839 and dlra17cmam296cmam508, respectively</td>
    </tr>
    <tr>
      <td>Our  continuing  product  <font color="blue">development</font>  efforts  may  lead to increased     <font color="blue"><font color="blue">expenditure</font>s which may increase</font> the amount of our losses</td>
    </tr>
    <tr>
      <td>Failure to achieve     <font color="blue">significant</font> sales of our <font color="blue">new products</font> in the future and continued losses     will reduce our <font color="blue">shareholders</font>’ equity, could <font color="blue">adversely</font> impact the continued     listing  of  our  stock on the NASDAQ Capital Market, and could have a     <font color="blue">significant</font> <font color="blue">adverse impact on</font> our stock price</td>
    </tr>
    <tr>
      <td>Our <font color="blue">cash <font color="blue">requirement</font>s</font> are <font color="blue">significant</font> and if we do not <font color="blue">generate sufficient</font>     funds from <font color="blue">operations</font> or obtain <font color="blue"><font color="blue">additional</font> financing</font> we may be unable to     continue our present product <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">cash <font color="blue">requirement</font>s</font> have been and <font color="blue">will continue</font> to be <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td>Our cash used in operating <font color="blue">activities</font> for the years ended <font color="blue">December </font>31, 2005,     2004 and 2003 was dlra4cmam604cmam174, dlra4cmam458cmam323 and dlra5cmam541cmam874, respectively</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">negative cash flows</font> are primarily related to operating losses, <font color="blue">discontinued</font>     <font color="blue">operations</font>, and <font color="blue">fluctuations</font> in working <font color="blue">capital items</font></td>
    </tr>
    <tr>
      <td>We  will  continue to use cash in 2006 for 1) product <font color="blue">development</font>     efforts, and to acquire or license products, <font color="blue">technologies</font> or businesses; 2)     corporate costs, primarily related to the cost of being a public company; 3)     <font color="blue"><font color="blue">preferred stock</font> dividends</font>; and 4) other working capital needs</td>
    </tr>
    <tr>
      <td>We completed     a dlra3dtta63 million financing in <font color="blue">December </font>2005 and January 2006 (<font color="blue">December </font>2005     Offering), but we will require <font color="blue"><font color="blue">additional</font> financing</font> in 2007 to complete or     <font color="blue">accelerate</font> the <font color="blue">development</font> of some of our high value emerging <font color="blue">new products</font>     and for working <font color="blue">capital <font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>The Company’s <font color="blue">Working Capital Line </font>    (Line) with Laurus Master Fund (Laurus) expired March 21, 2006</td>
    </tr>
    <tr>
      <td>On March 28,     2006, the Company renewed its <font color="blue">Working Capital Line </font>with Laurus</td>
    </tr>
    <tr>
      <td>Also on     March 28, 2006, the Company issued a new <font color="blue">Series of Preferred Stock to Laurus     </font>in exchange for dlra6cmam393cmam980 of the dlra7cmam850cmam000 Series F, G and H Preferred     Stock, resulting in a <font color="blue">deferral until</font> August 2007 through August 2008 of the     <font color="blue"><font color="blue">redemption payments</font> originally due under</font> the Company’s Series F-H Preferred     Stock</td>
    </tr>
    <tr>
      <td>These <font color="blue">redemption payments</font> were <font color="blue">originally due starting</font> August 2006     through <font color="blue">February </font>2007</td>
    </tr>
    <tr>
      <td><font color="blue">Management </font>believes that with the dlra3dtta63 million     financing  and  the <font color="blue">transactions with</font> Laurus, the Company has adequate     resources to fund working <font color="blue">capital <font color="blue">requirement</font>s</font> and product <font color="blue">development</font>     through <font color="blue">December </font>31, 2006</td>
    </tr>
    <tr>
      <td>You will experience <font color="blue"><font color="blue">additional</font> dilution</font> if the Company is not successful in     selling its <font color="blue">new products</font> in 2006 and 2007</td>
    </tr>
    <tr>
      <td>We intend to continue to invest <font color="blue">significant</font> funds in our new product     <font color="blue">development</font> programs and we will need to <font color="blue">raise <font color="blue">additional</font> funds</font> in order to     continue our product <font color="blue">development</font> and sales and marketing <font color="blue">activities</font> and for     other working capital needs in 2007</td>
    </tr>
    <tr>
      <td>In such event, we would expect to seek     to <font color="blue">raise such capital through</font> the sale of our <font color="blue">equity securities</font>, and, as a     result, <font color="blue"><font color="blue">shareholders</font> will</font> experience <font color="blue">significant</font> further dilution</td>
    </tr>
    <tr>
      <td>The failure to maintain shareholder’s equity above dlra2dtta5 million or market     <font color="blue">capitalization</font> of dlra35 million or to sustain a minimum share price of dlra1dtta00     per  share could result in delisting of our <font color="blue">shares on</font> the NASDAQ Stock     Market</td>
    </tr>
    <tr>
      <td>In order to retain our <font color="blue">listing on</font> the NASDAQ Capital Market, we are     required  to  maintain  (i)  <font color="blue">stockholders</font>’  equity of dlra2dtta5 million, or     (ii) <font color="blue">market value</font> of <font color="blue">common stock</font> of dlra35 million</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005,     our shareholder’s equity was dlra4cmam555cmam228</td>
    </tr>
    <tr>
      <td><font color="blue">As of April </font>5, 2006, the market     value  of our <font color="blue">common stock</font> was <font color="blue">approximately</font> dlra30 million</td>
    </tr>
    <tr>
      <td>Although our     <font color="blue">shareholders</font>’ equity is currently in excess of the dlra2dtta5 million minimum     <font color="blue">requirement</font> to maintain our listing, continued losses without increases in     <font color="blue">equity could</font> cause us to fall below this NASDAQ <font color="blue">requirement</font>, and if the     <font color="blue">market value</font> of our <font color="blue">common stock</font> is below dlra35 million at that time, we would     be required to <font color="blue">come into compliance</font> or <font color="blue">face delisting</font></td>
    </tr>
    <tr>
      <td>In order to retain     our <font color="blue">listing on</font> the NASDAQ Capital Market, we must also maintain a minimum     bid price of dlra1dtta00 per share for at least 30 consecutive trading days</td>
    </tr>
    <tr>
      <td>Our stock traded below this dlra1dtta00 minimum in the     March-May, 2003 timeframe and traded below dlra1dtta00 in March and April, 2006</td>
    </tr>
    <tr>
      <td>12       _________________________________________________________________    [48]Table of Contents       The failure to maintain our <font color="blue">listing on</font> the <font color="blue">NASDAQ Capital Market </font>would have     an adverse effect on our stock price and our ability to <font color="blue">attract <font color="blue">additional</font></font>     capital needed to sustain our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">outstanding <font color="blue">preferred stock</font></font> has a <font color="blue"><font color="blue">liquidation</font> preference</font> of dlra7cmam850cmam000,     which is in excess of our total <font color="blue">stockholders</font>’ equity</td>
    </tr>
    <tr>
      <td>Our <font color="blue">currently outstanding</font> <font color="blue">Convertible Preferred Stock </font>has a total     <font color="blue">Stated Value </font>of dlra7cmam850cmam000 as of March 27, 2006</td>
    </tr>
    <tr>
      <td>Upon the <font color="blue">dissolution</font>,     <font color="blue">liquidation</font>  or  winding  up  of the Corporation, <font color="blue">whether voluntary</font> or     <font color="blue">involuntary</font>, the holders of the Companyapstas Preferred Stock are entitled to     receive, before any payment or <font color="blue">distribution</font> shall be made on the common     stock out of the assets <font color="blue">of the <font color="blue">Corporation </font></font>available for <font color="blue">distribution</font> to the     <font color="blue">stockholders</font>, the <font color="blue">Stated Value </font>per share of the Companyapstas Preferred Stock     <font color="blue">then outstanding</font> and all accrued and <font color="blue">unpaid dividends</font></td>
    </tr>
    <tr>
      <td>In the event of a     <font color="blue">dissolution</font>, <font color="blue">liquidation</font> or <font color="blue">winding up</font> of the Corporation, holders of common     <font color="blue">stock may lose</font> their <font color="blue">entire investment</font></td>
    </tr>
    <tr>
      <td>If our product <font color="blue">development</font> programs are not successful, it will harm our     business</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of sophisticated laser-based systems and sensors, such     as our BioSentry, X-ray Microscope and our X-ray Nano Probe products, is a     lengthy and <font color="blue">capital intensive process</font> and is subject to <font color="blue">unforeseen risks</font>,     delays, problems and costs</td>
    </tr>
    <tr>
      <td>We have had limited success in <font color="blue">past product</font>     <font color="blue">development</font> efforts, including the failure to achieve <font color="blue">market <font color="blue">acceptance</font></font> of     our Collimated Plasma Lithography (CPL) products and in our efforts to     establish a standard <font color="blue"><font color="blue">semiconductor</font> products</font> business</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you     that we will be able to <font color="blue">successfully</font> develop our <font color="blue">new products</font>, or that     <font color="blue">unanticipated technical</font> or other <font color="blue">problems will</font> not occur <font color="blue">which would</font> result     in delays in our <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td><font color="blue">Achieving </font><font color="blue">market <font color="blue">acceptance</font></font> for our <font color="blue">new products</font> requires a <font color="blue">significant</font>     effort to <font color="blue">convince customers</font> to adopt our products and <font color="blue">technologies</font> over     other <font color="blue">alternative products</font> and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>In the case of each of our new     product <font color="blue">development</font> efforts, this requires <font color="blue">demonstrating</font> that our products     have superior performance to the <font color="blue">alternative products</font> and <font color="blue">technologies</font> and     are  more  cost-effective</td>
    </tr>
    <tr>
      <td>In addition to the <font color="blue">expenditure</font>s required to     complete and <font color="blue">commercialize</font> these products, this will require substantial     technical, marketing and <font color="blue">sales efforts</font> and the <font color="blue">expenditure</font> of <font color="blue">significant</font>     funds to create <font color="blue">customer awareness</font> of and demand for our products</td>
    </tr>
    <tr>
      <td>We cannot     assure you that our <font color="blue">new products</font> will achieve <font color="blue">significant</font> <font color="blue">market <font color="blue">acceptance</font></font>     in the future or result in <font color="blue">significant</font>ly increased levels of revenues</td>
    </tr>
    <tr>
      <td>In addition to the <font color="blue">technical performance</font> of our <font color="blue">BioSentry </font>and other     products, the success of the <font color="blue">BioSentry </font>and other <font color="blue">product lines</font> is <font color="blue">dependent</font>     in part on the Company’s estimates of the <font color="blue">potential market</font> for <font color="blue">such systems</font></td>
    </tr>
    <tr>
      <td>Because many of the expected markets for a <font color="blue">detection system such as</font> the     BioSentry, as well as for the Company’s X-ray source-related products, do     not presently exist, the Company has had to make a number of <font color="blue">assumptions</font>     about  the  size and needs of <font color="blue">such markets</font></td>
    </tr>
    <tr>
      <td>As a result, the Company’s     estimates  about  the  size and nature of the expected markets for the     <font color="blue">BioSentry </font>and other <font color="blue">products may</font> be <font color="blue">inaccurate</font> and the <font color="blue">ultimate markets</font>, and     the <font color="blue">actual sales</font> of <font color="blue">products into</font> those markets, could be <font color="blue">significant</font>ly less     than the Company’s current estimates reflect</td>
    </tr>
    <tr>
      <td>If the actual markets for the     Company’s <font color="blue">new products</font> are not of the magnitude expected, or if they do not     develop  at  the  rate the Company expects, the Company’s revenues and     <font color="blue">financial condition will</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on third party suppliers</font> of <font color="blue">various components</font> for our equipment     business and our business will be harmed if the supply of <font color="blue">key components</font> is     <font color="blue">interrupted</font> or <font color="blue">discontinued</font></td>
    </tr>
    <tr>
      <td>Our Research Division, Vermont Operation, and our Sensor Products Group     (BioSentry) are <font color="blue">dependent</font> on third party suppliers for <font color="blue">components used</font> in     the <font color="blue">development</font> and <font color="blue">manufacture</font> of our products</td>
    </tr>
    <tr>
      <td>If certain <font color="blue">key components</font>     are  delayed or unavailable, we might have to reengineer our products,     resulting  in  delays and <font color="blue">increased costs</font>, or we may have to pay other     suppliers more to obtain those components, which could <font color="blue">adversely</font> affect our     business</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">cost models</font> contemplate that <font color="blue">multiple suppliers</font>     and <font color="blue">greater volume purchases will bring down</font> the <font color="blue">manufacturing costs</font> to make     our <font color="blue">new systems</font> more <font color="blue">competitively priced</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we anticipate having <font color="blue">multiple sources</font> of supply for the     <font color="blue">components used</font> in our future production systems, there are <font color="blue">no assurances</font>     that  <font color="blue">additional</font>  <font color="blue">suppliers will materialize</font></td>
    </tr>
    <tr>
      <td>In particular, our X-ray     Microscope and X-ray Nano Probe products require certain X-ray <font color="blue">optics called</font>     zone  plates  that are <font color="blue">difficult</font> and expensive to <font color="blue">manufacture</font></td>
    </tr>
    <tr>
      <td>We have     identified suppliers of zone plates and have <font color="blue">also initiated</font> an effort to     <font color="blue">manufacture</font> zone plates in-house</td>
    </tr>
    <tr>
      <td>If we cannot obtain these zone plates when     needed at an acceptable cost, then we will need to rely on other optics,     which  would  involve <font color="blue">additional</font> re-engineering and related delays and     <font color="blue">additional</font> costs which could <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">BioSentry </font>    product <font color="blue">development</font> effort also relies on certain <font color="blue">complex optics</font></td>
    </tr>
    <tr>
      <td>If we     cannot obtain these <font color="blue">complex optics</font> when needed at an acceptable cost, then     we  may  have  to redesign the product, <font color="blue">which would</font> involve <font color="blue">additional</font>     re-engineering and related delays and <font color="blue">additional</font> costs which could <font color="blue">adversely</font>     affect our business</td>
    </tr>
    <tr>
      <td>13       _________________________________________________________________    [49]Table of Contents       The  success  of  our  business is <font color="blue">dependent</font> on our ability to compete     effectively, particularly against larger, more <font color="blue">established companies with</font>     <font color="blue">greater resources</font></td>
    </tr>
    <tr>
      <td>The  markets  for  our  products  are  <font color="blue">highly competitive</font> and are     <font color="blue">characterized by rapid technological</font> change and <font color="blue">evolving industry standards</font></td>
    </tr>
    <tr>
      <td>For example, although we are not aware of any products in the market for     detecting and <font color="blue">classifying microorganisms</font> similar to our <font color="blue">BioSentry </font>product,     <font color="blue">water utilities</font> and other <font color="blue">water industry customers currently employ</font> other     products and <font color="blue">technologies</font>, such as filters and <font color="blue">ultraviolet disinfection</font>     systems, to remove or <font color="blue">neutralize microorganisms from</font> the <font color="blue">water supply</font></td>
    </tr>
    <tr>
      <td>Our     X-ray Microscope and X-ray Nano Probe products provide alternative “soft”     X-rays for the <font color="blue">microscopy</font> and <font color="blue">materials processing markets</font></td>
    </tr>
    <tr>
      <td>Currently, the     intended users of soft X-rays must pay for time on large <font color="blue">synchrotrons</font> to     perform   their  intended  processes</td>
    </tr>
    <tr>
      <td>Alternatively,  for  biological     <font color="blue">experimentation</font>, other <font color="blue">technologies</font> are available, such as <font color="blue">transmission</font>     electron <font color="blue">microscopy</font>, to perform the types of analyses performed by our new     X-ray Microscope product</td>
    </tr>
    <tr>
      <td>While we believe that our new X-ray <font color="blue">products will</font>     provide  certain  functions  that the <font color="blue">current competitive products</font> and     <font color="blue">technologies</font> cannot provide (eg, lower capital and operating expense; more     rapid performance), there is a risk that our <font color="blue">intended customers may</font> not view     these <font color="blue">benefits as outweighing</font> the features of <font color="blue">established products</font> and     <font color="blue">technologies</font> (which include <font color="blue">better resolution</font> in the case of <font color="blue">transmission</font>     <font color="blue">electron microscopes</font> or <font color="blue">lower costs</font> in the case of <font color="blue">optical microscopes</font>)</td>
    </tr>
    <tr>
      <td>Further <font color="blue">development</font> by others of new or improved products, processes or     <font color="blue">technologies</font> may make our <font color="blue">products obsolete</font> or <font color="blue">less competitive</font></td>
    </tr>
    <tr>
      <td>Our ability     to compete is <font color="blue">dependent</font> on our ability to <font color="blue">continually enhance</font> and improve     our products and to <font color="blue">successfully</font> develop and market <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>Many of     our <font color="blue">competitors</font> have <font color="blue">greater financial</font>, managerial and technical resources     than we have</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will <font color="blue">successfully</font> differentiate     ourselves from our <font color="blue">competitors</font>, that the <font color="blue">relevant markets will</font> consider our     products to be superior to our <font color="blue">competitors</font>’ products or that we will be able     to adapt to <font color="blue">evolving markets</font> and <font color="blue">technologies</font>, develop <font color="blue">new products</font> or     achieve and maintain <font color="blue">technological advantages</font></td>
    </tr>
    <tr>
      <td>A substantial portion of our <font color="blue">current revenue depends on sales</font> to a few     customers</td>
    </tr>
    <tr>
      <td>We have <font color="blue">relied on <font color="blue">funding from</font></font> the <font color="blue">US Department of Defense </font>for     a <font color="blue">significant</font> portion of our research and <font color="blue">development</font> <font color="blue">activities</font> in the past     and expect <font color="blue">significant</font>ly less funding of our new product <font color="blue">development</font>s from     the <font color="blue">government</font> in the future</td>
    </tr>
    <tr>
      <td>To  date,  our  CPL <font color="blue">development</font> program has received in excess of     dlra62 million in <font color="blue">funding under</font> DARPA <font color="blue">contracts over</font> the past 10 years, with     dlra3dtta5 million and dlra3dtta7 million received in 2005 and 2004, respectively</td>
    </tr>
    <tr>
      <td>In     2005, <font color="blue">approximately</font> 82 percent of our revenues was <font color="blue">derived as</font> the prime     <font color="blue">contractor</font> or sub<font color="blue">contractor</font> for three <font color="blue">government</font> contracts</td>
    </tr>
    <tr>
      <td>One of the     contracts is issued to our <font color="blue">Research Division </font>by the US Army Research     Laboratory <font color="blue">sponsored by</font> DARPA for further <font color="blue">development</font> of our CPL system     (<font color="blue">DARPA Contract</font>)</td>
    </tr>
    <tr>
      <td>In February, 2005, we received the last dlra3dtta5 million in     <font color="blue">funding under</font> the <font color="blue">DARPA Contract</font></td>
    </tr>
    <tr>
      <td>No <font color="blue">further program funding</font> related to the     <font color="blue">DARPA Contract</font> is included in the United States Government’s budget and we     expect no further <font color="blue">funding under</font> this contract after the receipt of the     dlra3dtta5 million</td>
    </tr>
    <tr>
      <td>We continue to receive <font color="blue">funding from</font> the <font color="blue">Government </font>under a     separate DARPA/NAVAIR contract (NAVAIR Contract) for the <font color="blue">procurement</font> of     X-ray masks and for the <font color="blue">fabrication</font> of certain X-ray optics, to be used in     our X-ray Microscope and X-ray Nano Probe product <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>The     funding for the <font color="blue">NAVAIR Contract </font>has been <font color="blue">Congressionally </font>mandated and is     subject to the risk of losing <font color="blue">Congressional </font>support</td>
    </tr>
    <tr>
      <td>The DOD’s <font color="blue">overall budget</font>, and our <font color="blue">participation therein</font>, is subject to     reduction  <font color="blue">based upon</font> a number of factors, including <font color="blue">general budgetary</font>     <font color="blue">constraints</font>, shifting priorities of the specific <font color="blue">government</font>al agency which     sponsors the funding and our own <font color="blue">performance under</font> our <font color="blue">contracts with</font> the     Government</td>
    </tr>
    <tr>
      <td>We do not expect to receive <font color="blue">funding from</font> <font color="blue">government</font> sources at     similar levels in the future</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is <font color="blue">relying on</font> the sale of its new     products in 2006 and beyond, together with financing transactions, which     could include <font color="blue">strategic alliances</font>, to support continued product <font color="blue">development</font>     and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>To the extent we continue to invest in product <font color="blue">development</font>,     these <font color="blue">expenditure</font>s will increase our losses <font color="blue">accordingly</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">major source</font> of revenue has been the <font color="blue">subcontract between</font> JMAR’s     <font color="blue">Microelectronics Division </font>and General Dynamics Advanced Information Systems     (GDAIS) to  enhance  and  maintain the <font color="blue">semiconductor</font> wafer <font color="blue">fabrication</font>     processes installed at <font color="blue">the McClellan Air Force Base in Sacramento </font>for the     DMEA This work, <font color="blue">which started</font> in 1998, has resulted in a <font color="blue">new subcontract</font>     <font color="blue">each year out</font> of <font color="blue">funds available</font> in the DMEA’s <font color="blue">budget as</font> an element of the     Department of Defense’s Advanced Technology Support Program</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>    received dlra3dtta5 million in contracts in 2004, dlra2dtta3 million in <font color="blue">letter contracts</font>     in 2005 and the final <font color="blue">approximately</font> dlra1dtta9 million against a dlra4dtta2 million     <font color="blue">contract finalized</font> in <font color="blue">February </font>2006</td>
    </tr>
    <tr>
      <td>In March 2006, GDAIS informed the     Company that DMEA does not want to provide the <font color="blue">additional</font> funding required     to support the <font color="blue">costs imposed by both</font> JMAR and GDAIS on the <font color="blue">DMEA Contract </font>and     that the <font color="blue">funding will</font> only be sufficient to provide for one <font color="blue">contractor</font></td>
    </tr>
    <tr>
      <td>Unless  DMEA  and  GDAIS change their positions, JMAR will not receive     <font color="blue">additional</font> subcontract funding for the remainder of 2006 and beyond</td>
    </tr>
    <tr>
      <td>The     Company is not hopeful that this <font color="blue">decision will</font> change</td>
    </tr>
    <tr>
      <td>The viability of the     <font color="blue">Microelectronics Division </font>is <font color="blue">dependent</font> on continued <font color="blue">funding from</font> GDAIS/DMEA     In light of this recent <font color="blue">development</font>, the Company is evaluating the cost     control and <font color="blue">organizational actions</font> it needs to take in response to the     <font color="blue">probability</font> that the <font color="blue">funding will</font> not be continued</td>
    </tr>
    <tr>
      <td>14       _________________________________________________________________    [50]Table of Contents       Declines in our operating performance and other factors <font color="blue">adversely</font> affecting     the valuation of our business <font color="blue">units could ultimately</font> result in an <font color="blue">impairment</font>     of our goodwill</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, there was dlra4cmam415cmam932 in <font color="blue">goodwill reflected on</font>     our   balance   sheet,   all  of  which  is  related  to  our  Vermont     Operations/<font color="blue">Research Division </font>business unit</td>
    </tr>
    <tr>
      <td>We assess potential <font color="blue">impairment</font>s     to  our  goodwill  when  there  is  evidence that events or changes in     <font color="blue"><font color="blue">circumstances</font> indicate</font> that the carrying value may not be recoverable</td>
    </tr>
    <tr>
      <td>We     assess potential <font color="blue">impairment</font>s to <font color="blue">goodwill annually</font> and when there is evidence     that  events  or  changes in <font color="blue"><font color="blue">circumstances</font> indicate</font> that an <font color="blue">impairment</font>     <font color="blue">condition may</font> exist</td>
    </tr>
    <tr>
      <td>Factors <font color="blue">adversely</font> affecting the business unit’s future     <font color="blue">potential revenues</font> and cash flow, as well as factors <font color="blue">adversely</font> affecting the     Company’s market <font color="blue">capitalization</font>, will <font color="blue">adversely</font> affect the valuation of the     Company’s  goodwill  and  could lead to an <font color="blue">impairment</font> of the Company’s     goodwill</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> <font color="blue">impairment</font> loss would cause a <font color="blue">further increase</font> in     our <font color="blue">net losses with</font> a <font color="blue">corresponding reduction</font> in our <font color="blue">shareholders</font>’ equity</td>
    </tr>
    <tr>
      <td>Our <font color="blue">BioSentry </font><font color="blue">product may</font> be subject to various <font color="blue">government</font>al approvals that     may limit our ability to market and sell our product</td>
    </tr>
    <tr>
      <td>In some cases, the use of our <font color="blue">BioSentry </font><font color="blue">product by</font> the <font color="blue">water utility</font>     industry, the <font color="blue">commercial water bottling industry</font> and <font color="blue">others may</font> require     approval by <font color="blue">government</font>al regulators prior to the <font color="blue">commercial use</font> of such     units by our customers</td>
    </tr>
    <tr>
      <td>In other cases, the <font color="blue">acceptance</font> of our <font color="blue">BioSentry </font>    <font color="blue">product may</font> be <font color="blue">enhanced by certification</font> or other <font color="blue">approvals by industry</font>     groups or <font color="blue">government</font> regulators</td>
    </tr>
    <tr>
      <td>In the case of Olivenhain Municipal Water     District (OMWD), one of our customers, our <font color="blue">agreement with</font> OMWD to purchase     <font color="blue">BioSentry </font><font color="blue">production units</font> is <font color="blue">dependent</font> upon the <font color="blue">determination by</font> a state     regulator that the <font color="blue">BioSentry </font>unit may be implemented in lieu of an earlier     mandate that the <font color="blue">utility employ</font> other means to reduce the <font color="blue">concentration</font> of     <font color="blue">certain microorganisms</font> in its water</td>
    </tr>
    <tr>
      <td>The failure to obtain approval of     various state and federal agencies could <font color="blue">adversely</font> impact the sale of our     <font color="blue">BioSentry </font>products</td>
    </tr>
    <tr>
      <td>Our quarterly operating results may fluctuate <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>As a result, we     may fail to meet or exceed the <font color="blue">expectations</font> of <font color="blue">securities analysts</font> and     investors, which could cause our stock price to decline</td>
    </tr>
    <tr>
      <td>Our <font color="blue">quarterly revenues</font> and operating results have fluctuated in the     past and <font color="blue">may continue</font> to <font color="blue">vary from quarter</font> to <font color="blue">quarter due</font> to a number of     factors,  including the <font color="blue">risk factors set forth</font> in this section</td>
    </tr>
    <tr>
      <td>If our     operating results do not meet the <font color="blue">expectations</font> of <font color="blue">securities analysts</font> or     investors, our <font color="blue">stock price may decline</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">lose key personnel</font> or are unable to attract and retain <font color="blue">additional</font>,     <font color="blue">highly skilled personnel</font> required for the expansion of our <font color="blue">activities</font>, our     business will suffer</td>
    </tr>
    <tr>
      <td>Our success is substantially <font color="blue">dependent</font> on the efforts of <font color="blue">certain key</font>     personnel</td>
    </tr>
    <tr>
      <td>In particular, our new X-ray-based product <font color="blue">development</font> efforts     rely on the skill of <font color="blue">several key laser</font> and <font color="blue">laser plasma scientists</font> and     engineers and our <font color="blue">BioSentry </font>product <font color="blue">development</font> effort relies on the skills     of <font color="blue">several key technical personnel</font> in the areas of scattered-light-based     detection systems, algorithms used to interpret the results of scattered     light and microorganism morphology, as well as personnel experienced in the     water  industry</td>
    </tr>
    <tr>
      <td>The loss of such personnel would <font color="blue">adversely</font> affect our     business and prospects</td>
    </tr>
    <tr>
      <td>In such event, we <font color="blue">cannot assure</font> you that we would be     able to <font color="blue">employ qualified persons on terms</font> favorable to us</td>
    </tr>
    <tr>
      <td>In seeking and     retaining <font color="blue">qualified personnel</font>, we are required to <font color="blue">compete with companies</font>     having <font color="blue">greater financial</font> and other <font color="blue">resources than</font> we have</td>
    </tr>
    <tr>
      <td>Since our future     success  is  <font color="blue">dependent</font> upon our ability to retain or <font color="blue">attract qualified</font>     personnel,  our  failure  to do so could have an <font color="blue">adverse impact on</font> our     business</td>
    </tr>
    <tr>
      <td>Asserting,  defending  and maintaining <font color="blue">intellectual property rights</font> is     <font color="blue">difficult</font> and costly and the failure to do so <font color="blue">could harm</font> our ability to     compete and the results of our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  rely,  to a <font color="blue">significant</font> extent, on patents, trade secrets and     <font color="blue">confidentiality agreements</font> to protect our <font color="blue">proprietary <font color="blue">technology</font></font></td>
    </tr>
    <tr>
      <td>We cannot     assure you as to the breadth or degree of <font color="blue">protection which existing</font> or     future  patents,  if  any,  <font color="blue">may afford us</font>, or that <font color="blue">patents will</font> not be     <font color="blue">circumvented</font>  or invalidated, or that our products do not and will not     <font color="blue"><font color="blue">infringe on</font> patents</font> or <font color="blue">violate <font color="blue">proprietary rights</font></font> of others</td>
    </tr>
    <tr>
      <td>In the event a     patent <font color="blue">infringement</font> claim is asserted against us, or we are required to     enforce our rights under an issued patent, the cost of such actions may be     very high, whether or not we are successful</td>
    </tr>
    <tr>
      <td>While we are unable to predict     what  <font color="blue">such costs</font>, if any, will be if we are obligated to pursue patent     <font color="blue">litigation</font>, our ability to fund our <font color="blue">operations</font> and to pursue our business     <font color="blue">goals may</font> be <font color="blue">substantially impaired</font></td>
    </tr>
    <tr>
      <td>15       _________________________________________________________________    [51]Table of Contents            Our BioSentry™ <font color="blue">product uses scattered light</font> to detect particles in     fluids</td>
    </tr>
    <tr>
      <td>This field is the subject of substantial <font color="blue">patent activity</font></td>
    </tr>
    <tr>
      <td>We have     <font color="blue">entered into</font> <font color="blue">License Agreements </font>with PointSource Technologies, The LXT Group     and NASA, covering the license of <font color="blue">technologies</font> related to the <font color="blue">BioSentry </font>    product  area</td>
    </tr>
    <tr>
      <td><font color="blue">Although JMAR </font>believes that the patents and <font color="blue">technology</font>     <font color="blue">licenses from</font> PointSource, LXT and NASA, as well as the <font color="blue">technology</font> that we     have developed in-house, provide adequate coverage for our current <font color="blue">BioSentry </font>    product, we can give you <font color="blue">no assurances</font> that the <font color="blue">technologies</font> that we want or     need to use in the future in this <font color="blue">field may</font> not <font color="blue">infringe on</font> the patents or     <font color="blue">proprietary rights</font> of others</td>
    </tr>
    <tr>
      <td>If we need to use <font color="blue">technologies</font> owned by third     parties in <font color="blue">connection with</font> our <font color="blue">BioSentry </font>products and <font color="blue">cannot license them on</font>     <font color="blue">reasonable terms</font>, our ability to develop, <font color="blue">manufacture</font> and <font color="blue">commercialize</font> our     <font color="blue">BioSentry </font><font color="blue">products will</font> be <font color="blue">adversely</font> impacted, <font color="blue">which would</font> <font color="blue">adversely</font> affect     our business and our stock price</td>
    </tr>
    <tr>
      <td>If our <font color="blue">outstanding options</font> and warrants are exercised and if our preferred     stock is converted it will result in substantial dilution</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had outstanding 38cmam823cmam158 shares of common     stock</td>
    </tr>
    <tr>
      <td><font color="blue">Substantially </font>all of the <font color="blue">outstanding shares</font> of the Company’s common     stock are <font color="blue">freely tradable without restriction</font> or <font color="blue">further registration under</font>     the <font color="blue">Securities Act</font></td>
    </tr>
    <tr>
      <td><font color="blue">Affiliates </font>may sell the shares they own pursuant to     Rule 144, subject to certain notice filing and <font color="blue">volume limitations</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, there were 9cmam783cmam848 shares of <font color="blue">common stock</font>     subject to <font color="blue">issuance upon exercise</font> of <font color="blue">outstanding options</font> and warrants</td>
    </tr>
    <tr>
      <td>The outstanding <font color="blue">Series G Preferred Stock </font>is     convertible  into  shares  of  <font color="blue">common stock</font> at dlra2dtta00 per share and the     outstanding <font color="blue">Series I Preferred Stock </font>is <font color="blue">convertible into shares</font> of common     stock at dlra1dtta16 per share</td>
    </tr>
    <tr>
      <td>Subject to a <font color="blue">contractual limitation on total</font>     <font color="blue">beneficial ownership by</font> Laurus to 4dtta99prca of our <font color="blue">common stock</font>, the Series G     and I Preferred Stock is convertible into 6cmam240cmam062 shares of <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">connection with</font> an offering of <font color="blue">common stock</font> and warrants completed     in February, 2005 (<font color="blue">February </font>2005 Offering), <font color="blue">certain investors</font> were granted     the  right  to  purchase  up to 30prca of <font color="blue">certain future offerings</font> of our     <font color="blue">securities on</font> the <font color="blue">same terms as</font> are offered in <font color="blue">such future offerings</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>right <font color="blue">continues until</font> February, 2007</td>
    </tr>
    <tr>
      <td>In <font color="blue">connection with</font> the execution of a     License  Agreement with PointSource Technologies, LLC (PointSource) in     January,  2005, affiliates of PointSource (PointSource Investors) were     granted the right to purchase <font color="blue">approximately</font> 1dtta66prca of certain completed     offerings  of our <font color="blue">securities on</font> the <font color="blue">same terms as</font> were offered in such     offerings</td>
    </tr>
    <tr>
      <td>This right must be exercised within 20 days after we give notice     to the <font color="blue">PointSource Investors </font>of the <font color="blue">completion</font> of a <font color="blue">securities offering</font></td>
    </tr>
    <tr>
      <td>This right <font color="blue">continues until</font> July, 2006</td>
    </tr>
    <tr>
      <td>To the extent that <font color="blue">outstanding options</font>, warrants and other purchase     rights are <font color="blue">exercised prior</font> to their expiration dates, <font color="blue">additional</font> funds will     be  paid  into  us  at the expense of dilution to the interests of our     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Moreover, the terms upon which we will be able to obtain     <font color="blue">additional</font> equity capital may be <font color="blue">adversely</font> affected since the holders of     <font color="blue">outstanding options</font> and warrants and other securities can be expected to     exercise or <font color="blue">convert them at</font> a time when we would, in all likelihood, be able     to  obtain any needed <font color="blue">capital on terms</font> more favorable to us than those     provided in <font color="blue">such securities</font></td>
    </tr>
    <tr>
      <td>The sale of the <font color="blue">shares issued upon exercise</font> of     our outsanding warrants and options and <font color="blue">conversion</font> of our Convertible Note     and Preferred Stock could <font color="blue">adversely</font> affect the <font color="blue">market price</font> of our common     stock</td>
    </tr>
    <tr>
      <td>If <font color="blue">product liability</font> claims are <font color="blue">brought which exceed</font> our <font color="blue">liability insurance</font>     limits our business would be harmed</td>
    </tr>
    <tr>
      <td>We may be exposed to potential <font color="blue">product liability</font> claims arising out of     the use of our products</td>
    </tr>
    <tr>
      <td>Although we maintain <font color="blue">product liability</font> insurance on     our <font color="blue">current products</font>, we <font color="blue">cannot assure</font> you that <font color="blue">such <font color="blue">insurance will</font></font> be     sufficient to <font color="blue">cover potential</font> claims or that the <font color="blue">present level</font> of coverage     will  be  available in the future at a <font color="blue">reasonable cost</font></td>
    </tr>
    <tr>
      <td>A partially or     <font color="blue">completely uninsured successful</font> claim <font color="blue">against us could</font> have a material     adverse  affect  on our business</td>
    </tr>
    <tr>
      <td>There can be no assurance that as we     complete  the  <font color="blue">commercialization</font> and introduction of <font color="blue">new products</font> that     <font color="blue">insurance will</font> be <font color="blue">available on economically</font> favorable terms or in amounts     adequate to cover the <font color="blue">risks associated with</font> these <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>We do not <font color="blue">presently intend</font> to <font color="blue">pay cash dividends</font> to our <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">never paid cash dividends on</font> our <font color="blue">common stock</font> and intend, for     the <font color="blue">foreseeable future</font>, to retain our earnings, if any, to finance our     business</td>
    </tr>
    <tr>
      <td>Future <font color="blue">dividend policy will depend on</font> our earnings, capital     <font color="blue">requirement</font>s,  financial  condition,  <font color="blue">debt covenants</font> and other factors     considered <font color="blue">relevant by</font> our <font color="blue">Board of Directors</font></td>
    </tr>
    <tr>
      <td>16       _________________________________________________________________    [52]Table of Contents       Our ability to use our <font color="blue">entire net</font> operating <font color="blue">loss carryforward</font> is limited by     prior changes in ownership and may be further limited in the future</td>
    </tr>
    <tr>
      <td>We have <font color="blue">federal net</font> operating loss carry-forwards of <font color="blue">approximately</font>     dlra58 million at <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td><font color="blue">These NOLs </font>expire <font color="blue">incrementally through</font>     2025</td>
    </tr>
    <tr>
      <td><font color="blue">Realization  </font>of future tax benefits from <font color="blue">utilization</font> of our net     operating loss carry-forwards for income tax purposes is limited by changes     in ownership in 1990, 1992 and 1993</td>
    </tr>
    <tr>
      <td>Of the total NOLs, <font color="blue">annual limitations</font>     of dlra695cmam000 apply to <font color="blue">approximately</font> dlra2dtta9 million of the NOLs and the balance     is subject to these <font color="blue">annual limitations</font></td>
    </tr>
    <tr>
      <td>In addition, the net operating     losses  of  acquired  companies are also subject to separate change of     <font color="blue">ownership limitations</font></td>
    </tr>
    <tr>
      <td>Due to our taxable losses in the <font color="blue">past three years</font>, we     have  <font color="blue">been unable</font> to take advantage of the benefits of these NOLs</td>
    </tr>
    <tr>
      <td>The     <font color="blue">realization</font> of the benefits of these NOLs is <font color="blue">dependent</font> upon our <font color="blue">recognition</font>     of <font color="blue">taxable income</font> in the <font color="blue">future prior</font> to the expiration of the NOLs</td>
    </tr>
    <tr>
      <td>If we <font color="blue">issue shares</font> of <font color="blue"><font color="blue">preferred stock</font> with greater rights than</font> the common     stock, it could result in the decrease in <font color="blue">market price</font> of the <font color="blue">common stock</font>     and <font color="blue">could delay</font> or prevent a change in control of us</td>
    </tr>
    <tr>
      <td>Our <font color="blue">Board of Directors</font> is authorized to issue up to 5cmam000cmam000 shares of     <font color="blue">preferred stock</font>, of which 785cmam000 shares of <font color="blue">Series G and I Preferred Stock     </font>were <font color="blue">outstanding as</font> of March 28, 2006</td>
    </tr>
    <tr>
      <td>As a result of prior issuances of a     total  of  1cmam450cmam000  shares of <font color="blue">preferred stock</font> that were <font color="blue">subsequently</font>     converted into <font color="blue">common stock</font>, a total of 2cmam765cmam000 shares of Preferred Stock     are available for issuance in the future</td>
    </tr>
    <tr>
      <td>Our <font color="blue">Board of Directors</font> has the     power to establish the dividend rates, <font color="blue"><font color="blue">liquidation</font> preference</font>s, voting     rights, redemption and <font color="blue">conversion</font> terms and <font color="blue">privileges with respect</font> to any     series of <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>The issuance of any shares of <font color="blue">preferred stock</font>     having rights superior to those of the <font color="blue">common stock</font> may result in a decrease     in the value or <font color="blue">market price</font> of the <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Holders of <font color="blue">preferred stock</font>     may have the right to receive dividends, certain <font color="blue">preferences</font> in <font color="blue">liquidation</font>     and <font color="blue">conversion</font> rights</td>
    </tr>
    <tr>
      <td>The issuance of <font color="blue">preferred stock</font> could, under certain     <font color="blue">circumstances</font>, have the effect of delaying, deferring or preventing a change     in control of <font color="blue">us without further vote</font> or <font color="blue">action by</font> the <font color="blue">stockholders</font> and may     <font color="blue">adversely</font> affect the voting and other rights of the holders of <font color="blue">common stock</font></td>
    </tr>
  </tbody>
</table>